Advances in HER2-targeted therapies have improved the survival of patients with HER2-
positive breast cancer. The standard-of-care treatment for localized disease has been …

The ERBB family of receptor tyrosine kinases has been implicated in carcinogenesis for over
three decades with rigorous attention to EGFR and HER2. ERBB receptors, consisting of …

Purpose: Based on promising preclinical data, we conducted a single-arm phase II trial to
assess the clinical benefit rate (CBR) of neratinib, defined as complete/partial response …

Research on the epidermal growth factor (EGF) family and the family of receptors (EGFR)
has progressed rapidly in recent times. New crystal structures of the ectodomains with …

Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through
activation of alternative survival pathways or reactivation of the HER signaling network. Here …

Human epidermal growth factor receptor 2 (HER2) protein overexpression or gene
amplification is an important predictive biomarker for identifying patients with breast cancer …

Mutations in ERBB2, the gene encoding epidermal growth factor receptor (EGFR) family
member HER2, are common in and drive the growth of “HER2-negative”(not ERBB2 …

Purpose: The advent of next-generation sequencing technologies has enabled the
identification of several activating mutations of Erb-B2 receptor tyrosine kinase 2 (ERBB2) …

Breast cancer is the second leading cause of cancer death among women. Human
epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive …

Over the past two decades, cancer treatment has benefited from having a significant
increase in the number of targeted drugs approved by the United States Food and Drug …